The synthetic pentasaccharide SR 90107A/Org 31540 does not release lipase activity into the plasma

Thrombosis Research

Volumn 86, Issue 4, 1997, Pages 325-332

  Hoffmann, P ^a   Bernat, A ^a   Dumas, A ^a   Petitou, M ^a   Herault J P ^a   Herbert, J M ^a  

^a SANOFI   (France)

Author keywords

Heparin; Low molecular weight heparin; Pentosan polysulphate; Plasma lipase activity; SR 90107A Org 31540

Indexed keywords

FONDAPARINUX; HEPARIN DERIVATIVE; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PENTASACCHARIDE; PENTOSAN POLYSULFATE; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTICOAGULATION; ARTICLE; ATHEROGENESIS; DOSE RESPONSE; DRUG MECHANISM; ENZYME ACTIVITY; INTRAVENOUS DRUG ADMINISTRATION; LIPOPROTEIN METABOLISM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOSIS;

ANIMALS; DRUG ADMINISTRATION SCHEDULE; FATTY ACIDS; FIBRINOLYTIC AGENTS; INJECTIONS, INTRAVENOUS; LIPASE; MALE; OLIGOSACCHARIDES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0030755695     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(97)00075-3     Document Type: Article

References (23)

1. OLIVECRONA T, BENGTSSON-OLIVECRONA G. Lipoprotein lipase and hepatic lipase. Curr. Opin. Lipidol., 4, 187-96, 1993.
2. KURIEN VA, OLIVER MF. A metabolic cause for arrhythmias during acute myocardial hypoxia. Lancet; i: 813-15, 1970.
3. TANSEY MJB, OPIE LH. Relation between plasma free fatty acids and arrhythmias within the first twelve hours of acute myocardial infarction. Lancet; ii, 419-22, 1983.
4. ZILVERSMIT DB. A proposal linking atherogenesis to the interaction of endothelial lipoprotein lipase with triglyceride-rich lipoproteins. Circ. Res., 33, 633-37. 1973.
5. MONREAL M, LAFOZ E, URRUTIA A, RONCALES J, GALIMANY R, BIOSCA C, COROMINAS A. Effects of long-term therapy with heparin or low molecular weight heparin on serum lipid levels. Haemostasis, 25, 283-87, 1995.
6. GOLDBERG DM, CHAJEK-SHAUL T Effect of chronic heparin administration on serum lipolytic activity and some aspects of lipid metabolism. Biochim. Biophys. Acta. 1047:1990;103-111.
7. CHEVREUIL O, HULTIN M, OSTERGARD P, OLIVACRONE T. Depletion of lipoprotein lipase after heparin administration. Arterioscler. Thromb., 13, 1391-96, 1993.
8. ARNADOTTIR M, KURKUS J, NILSSON-EHLE P. Different types of heparin in haemodialysis: long-term effects on post-heparin lipases. Scand. J. Clin. Lab. Invest. 54, 515-21, 1994.
9. PERSSON E, NORDENSTRÖM J, HAGENFELDT L, NILSSON-EHLE P Plasma lipolytic activity after subcutaneous administration of heparin and a low molecular weight heparin fragment. Thromb. Res. 46:1987;697-704.
10. MERCHANT ZM, ERBE EE, EDDY WP, PATEL D, LINHARDT RJ. Effect of very low molecular weight heparin-derived oligosaccharides on lipoprotein lipase release in rabbits. Atherosclerosis, 62, 151-58, 1986.
11. PARTHASARATHY N, GOLDBERG IJ, SIVARAM P, MULLOY B, FLORY DM, WAGNER WD. Oligosaccharide sequences of endothelial cell surface heparan sulfate proteoglycan with affinity for lipoprotein lipase. J. Biol. Chem., 35, 22391-96, 1994.
12. PETITOU M, DUCHAUSSOY P, BERNAT A, HOFFMANN P, HERBERT JM. A synthetic heparin/heparan sulfate-like decasaccharide releases lipase in vivo. chemical synthesis and biological activity. Biomed. Chem. Lett., submitted.
13. BAGINSKY ML. Measurement of lipoprotein lipase and hepatic triglyceride lipase in human postheparin plasma. In: JM Lowenstein ed, Methods in enzymology, Vol. 72, Academic Press, New York, 325-338, 1981.
14. BERNAT A, HOFFMANN P, HERBERT JM. Antagonism of SR 90107A/Org 31540 - induced bleeding by protamine sulphate in rats and mice. Thromb. Haemost., 76, 715-9, 1996.
15. HOBBELEN PMJ, VAN DINTHER TG, VOGEL GMT, VAN BOECKEL CAA, MOELKER HCT, MEULEMAN DG. Pharmacological profile of the chemically synthesized antithrombin III binding fragment of heparin (pentasaccharide) in rats. Thromb. Haemost., 63, 265-70, 1990.
16. BERNAT A, HERBERT JM. Protamine sulfate inhibits pentasaccharide (SR 80027)-induced bleeding without affecting its antithrombotic and anti-factor Xa activity in the rat. Haemostasis, in press.
17. WILLIAMS SP, JOHNSON EA. Release of lipoprotein lipase in rats by heparin and other sulphated polysaccharides. Thromb. Res., 55, 361-68, 1989.
18. BARROWCLIFFE TW, MERTON RE, GRAY E, THOMAS DP. Heparin and bleeding: an association with lipase release. Thromb. Haemost., 60, 434-36, 1988.
19. r heparin is as potent as conventional heparin in releasing lipoprotein lipase, but is less effective in preventing hepatic clearance of the enzyme. Biochem. J., 273, 747-52, 1991.
20. VILARO S, LLOBERA M, BENGTSSON-OLIVECRONA G, OLOVECRONA T. Lipoprotein lipase uptake by the liver. Am. J. Physiol., 254, G711-22, 1988.
21. NILSSON-EHLE P, GARFINKEL AS, SCHOTZ MC. Lipolytic enzymes and plasma lipoprotein metabolism. Ann. Rev. Biochem., 49, 667-93, 1980.
22. PERSSON E, NORDENSTRÖM J, NILSSON-EHLE P, HAGENFELDT L. Lipolytic and anticoagulant activities of a low molecular weight fragment of heparin. Eur. J. Clin. Invest., 15: 215-20, 1985.
23. RUDMAN D, BIXLIER TJ, DEL RIO AE. Effect of free fatty acids on binding of drugs to bovine serum albumin by human serum albumin and by rabbit serum. J. Pharmacol. Exp. Ther., 176, 261-71, 1971.